SCIENTIFIC CONSULTATION PROGRAMME & GLOBAL ANTIBIOTIC RESEARCH AND DEVELOPMENT (GARD) PARTNERSHIP Developing new antibiotic treatments, promoting responsible use, and ensuring access for all A joint WHO/DNDi initiative incubated by DNDi in support of the Global Action Plan for Antimicrobial Resistance PARTICIPANTS Institut Pasteur, France / 29 February 2016
Global Antibiotic R&D (GARD) Partnership Scientific Consultation Institut Pasteur, 29 February 2016 9:00 Welcome Remarks Christian Bréchot, President Institut Pasteur 9:10 Introduction, GARD Incubation & DNDi s Role Bernard Pécoul, Executive Director, DNDi 9:20 Update on WHO Global Action Plan on Antimicrobial Resistance Liz Tayler, WHO AMR Secretariat 9:30 Key Criteria, Milestones, and Sourcing of Initial Short and Medium-Term GARD Projects Jean-Pierre Paccaud, Business Development Director, DNDi 9:40 Embedding Conservation and Access into Each Project from the Start Manica Balasegaram, Executive Director, MSF Access Campaign 9:50 Bringing Diagnostics into the Equation Bill Rodriguez, Chief Medical Officer, FIND (via VC) Combination Issues for Existing Antibiotics 10:00 Overview of Antibiotic Drug Combination Issues Anthony Coates, Medical Microbiology Institute, St George's, University of London 10:15 Antibiotic Resistance Breakers for Use in Combinations David Brown, Antibiotics Research UK (ANTRUK) 10:30 Coffee Break Proposed Project Presentations & Discussion Chairs: Liz Tayler and Manica Balasegaram 11:00-11:30 Open Research Platform for Antibiotic Combinations & Open Platform for Improving Usage of Old Antibiotics (dosing regimens, indications) Ursula Theuretzbacher, Center for Anti-infective Agents Vienna / Angela Huttner, University Hospitals of Geneva 11:30-11:40 Sanofi s Antibiotic Drug Combinations and Formulations Work Laurent Fraisse / Michael Mourez / Nathalie Moniot-Ville, Sanofi 11:40-12:10 Oral Tebipenem for Extended Spectrum Beta Lactamase (ESBL) producing Enterobacteriaceae + New Polymyxin Formulations Visanu Thamlikitkul, Mahidol University 12:10-12:40 Novel Treatment Opportunities for Acute Melioidosis and Other Infections Caused by Intracellular Pathogens Jutta Heim, Evolva & Jo Larsen, BARDA 1 P a g e
12:40-13:45 Lunch Break 13:45 14:15 Overview of Needs on the Ground and Surveillance Issues The Case of India Kamini Walia, Indian Council of Medical Research 14:15-14:45 Addressing Antibiotic Treatment of Neonatal & Infant SBI in the Context of High MDRGM Mike Sharland, NHS UK / Paul Heath, St. Georges Vaccine Institute 14:45-15:15 New Formulations of Amoxicillin/Clavulanic Acid and Challenges of Heat Stability Marie-Claude Bottineau, MSF / Emmanuel Baron, Epicentre / Jean-René Kiechel, DNDi 15:15-15:30 Astellas Drug Formulation Overview Hasegawa Yu, Astellas Pharma Inc. 15:30-16:00 Coffee Break 16:00 16:30 Zoliflodacin for the Management of Uncomplicated Gonorrhoea Robin Isaacs, Entasis Therapeutics (via VC) 16:30-17:00 Enteric Fever Hellen Gelband, Center for Disease Dynamics, Economics & Policy / Chris Parry, London School of Hygiene and Tropical Medicine and Nagasaki University (via VC) / Buddha Basnyat, Oxford University Clinical Research Unit, Nepal (via VC) 17:00-17:15 Targeting the Cell Wall Elongation Machinery Ivo Gomperts Boneca, Institut Pasteur 17:15-18:15 Discussion and Conclusions on Priority Areas Presented throughout the Day 18:15 18:30 Closing Remarks and Next Steps 18:30 Farewell Cocktail 2 P a g e
LIST OF PARTICIPANTS Manica Balasegaram, MSF Access Campaign, Switzerland Brendan Barnes, EFPIA, Belgium Emmanuel Baron, Epicentre, France Buddha Basnyat, Oxford University Clinical Research Unit, Nepal (via VC) Esther Bettiol, Hôpitaux Universitaires de Genève / DRIVE AB, Switzerland Niresh Bhagwandin, MRC, South Africa Pierre-Etienne Bost, formerly Institut Pasteur, France Marie-Claude Bottineau, MSF, Switzerland Christian Bréchot, Institut Pasteur, France David Brown, ANTRUK, UK Christian Brun-Buisson, Ministry of Health, France Anthony Coates, St George's University of London, UK Tim Eckemanns, Robert Koch Institute, Germany Laurent Fraisse, Sanofi, France Hellen Gelband, Center for Disease Dynamics, Economics & Policy, USA Ivo Gomparts-Boneca, Institut Pasteur, France Laurent Gutmann, Hôpitaux Universitaires Paris Ouest / Hôpital Européen Georges Pompidou, France Ruben Hartkoorn, Institut Pasteur Lille, France Yu Hasegawa, Astellas, Japan Paul Heath, St. Georges Vaccine Institute, UK Jutta Heim, Evolva, Switzerland Angela Huttner, HUG, Switzerland Robin Isaacs, Entasis Therapeutics, USA (via VC) Tim Jinks, Wellcome Trust, UK Nadia Khelef, Institut Pasteur, France Jean-René Kiechel, DNDi, Switzerland 3 P a g e
Gabrielle Landry Chappuis, DNDi, Switzerland Joseph Larsen, Broad Spectrum Antimicrobials Program at the Biomedical Advanced Research Development Authority (BARDA), Department of Health & Human Services, USA Andrès McAllister, formerly Debio, Switzerland Nathalie Moniot-Ville, Sanofi, France Michael Mourez, Sanofi, France Jean-Pierre Paccaud, DNDi, Switzerland Chris Parry, London School of Hygiene and Tropical Medicine and Nagasaki University, Japan (via VC) Bernard Pécoul, DNDi, Switzerland Bertrand Schwartz, Agence Nationale de la Recherche, France Lynn Silver, LL Silver Consulting, USA (via VC) Kathy Talkington, The Pew Charitable Trusts, USA Elizabeth Tayler, WHO, Switzerland Visanu Thamlikitkul, Mahidol University, Thailand Farzam Vaziri, Institut Pasteur, Iran Kamini Walia, ICMR, India Teodora Wi, WHO, Switzerland Meeting contacts: Jean-Pierre Paccaud jppaccaud@dndi.org Gabrielle Landry glandry@dndi.org Cover photo: Copyright Swiss TPH 4 P a g e